IsleNova Cell Therapeutics is advancing the next generation of islet cell therapy and regenerative medicine — combining deep clinical expertise with innovative cellular technologies.
Our mission is to expand access to safe and effective cell-based therapies for patients with pancreatic diseases, including chronic pancreatitis and type 1 diabetes. We combine deep clinical expertise with innovative cellular technologies to deliver high-quality islet cell therapies that prioritize patient safety and long-term outcomes.
Our islet cell specialists have participated in more than 200 clinical islet isolation procedures and are among the most experienced teams in the United States in total pancreatectomy with islet autotransplantation (TPIAT). This extensive expertise forms the foundation of IsleNova's commitment to excellence in islet cell processing.
Everything we do is guided by a commitment to patient safety, clinical excellence, and translational innovation.
Whether you're a physician exploring a future partnership or an investor aligned with our mission, we'd like to connect.